SCHEMBL5577994

SCHEMBL5577994

CS(=O)(=O)N(Cc1ccccc1)Cc1ccccc1C1CCN(Cc2ccc(F)cc2)CC1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
ACHE P22303 2/20 0.47
BCHE P06276 1/20 0.47
BACE1 P56817 1/20 0.47
GAA P10253 2/20 0.47
KDM4E B2RXH2 1/20 0.47
LMNA P02545 1/20 0.47
SIGMAR1 Q99720 2/20 0.44
DRD2 P14416 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
RECQL P46063 1/20 0.44
PER2 O15055 1/20 0.43
CRY1 Q16526 1/20 0.43
CRY2 Q49AN0 1/20 0.43
ALDH1A1 P00352 1/20 0.43
NR1H2 P55055 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5577707 0.94 MEN1 (0.45) MEN1KMT2AACHEBCHEBACE1
SCHEMBL5577284 0.94 MCHR1 (0.43) MEN1KMT2AACHEBCHEBACE1
SCHEMBL5577766 0.91 APLNR (0.48) MEN1KMT2AACHESIGMAR1ALDH1A1
SCHEMBL5577363 0.91 LMNA (0.52) MEN1KMT2AACHEBCHEBACE1
SCHEMBL5577830 0.91 MEN1 (0.49) MEN1KMT2AACHEBCHEBACE1
SCHEMBL5577438 0.91 KDM4E (0.44) MEN1KMT2AACHEBCHEBACE1
SCHEMBL5577267 0.91 DRD2 (0.42) MEN1KMT2AACHEBCHEBACE1
SCHEMBL5577935 0.91 SIGMAR1 (0.48) MEN1KMT2AACHEBCHEGAA
SCHEMBL5577328 0.90 LMNA (0.44) MEN1KMT2AACHEBCHEBACE1
SCHEMBL5577351 0.89 MEN1 (0.54) MEN1KMT2AACHEBCHEKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043079-A1 Heterocyclic compound containing nitrogen atom and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-02-22 US disclosed
EP-1616862-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043079-A1 Heterocyclic compound containing nitrogen atom and use thereof HLA-DRB1, MIF, HLA-C MEN1 748/4885KMT2A 3527/4885ACHE 1504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.